Big data is a game-changer in many industries. The healthcare sector can gain even more than most, considering how advances here can save lives, not just money. Medicine development, in particular, could take some massive steps forward thanks to big data.
Developing a new medicine is a long, expensive process. It takes an
The typical development timeline falls into five overall phases. First, scientists must discover drug candidates, which are molecules that show potential to address a given condition. Next, they perform preclinical research to test and turn them into usable medicines.
Once pharmaceutical companies have a medicine, they must test it through a series of clinical trials. This is a four-stage process, and
After a medicine gets FDA approval, pharma companies can release it to the public. However, they still need to monitor it. This last stage of development involves ongoing monitoring to watch for any issues that didn’t come up in clinical trials or the FDA review.
Big data significantly improves almost every stage of this process. Here’s a closer look at its growing role in medicine development.
The first and one of the most impactful applications of big data in drug development is in the discovery phase. Large data volumes lay the groundwork for machine learning models to simulate interactions between various molecules. These AI models can find promising medicine candidates in record time.
Some AI drug discovery tools have identified potential treatments
Similarly, big data can make finding opportunities for new medicines easier. Creating an effective new treatment is largely a matter of finding an area where current options don’t meet everyone’s needs. Medical data from across demographics can reveal these gaps so pharma companies know what to look into.
This kind of predictive analytics is already common in healthcare. Some companies use big data
Big data also has extensive applications for the lengthy clinical trial phase. First, it can help identify ideal testing areas. Finding a population with enough willing patients with needed conditions and sufficient diversity is challenging. Collecting and analyzing big data on an area’s demographics makes it much faster.
Pharma companies can also pull big data from these trials once they’re underway. Collecting as much real-time information as possible throughout this testing process gives researchers the evidence they need for future FDA review. Big data’s velocity also means they can spot and address potential safety issues sooner.
Big data can also improve the post-market monitoring stage of medicine development. The FDA recalls
Gleaning data across various sources and locations for warning signs of medicine-related issues helps regulators detect problems early. They can then modify the drug itself, its prescription recommendations, or anything else to protect people’s health.
As beneficial as these use cases are, big data faces some obstacles in healthcare. Chief among these is the issue of patient privacy. Regulations like HIPAA make it challenging to access some medical records, and big data applications must ensure privacy to avoid leaking sensitive health information.
Big data tools also often come with a learning curve. Many pharmaceutical companies
Costs are another problem. Drug development is already expensive, and the digital infrastructure and AI software needed to store and process big data are far from cheap. Consequently, smaller pharma businesses may struggle to use this technology to its full extent.
Thankfully, there are possible solutions to these issues. A promising
While it’s still challenging to attract tech talent, pharma businesses can tackle shortages by reskilling their existing workforce. Many big data and AI platforms are also becoming increasingly user-friendly as this market matures. Consequently, these talent gaps will become less of a concern over time.
Similarly, big data costs will fall as technology improves and the market grows. Pharma companies can also spread out these costs through gradual implementation. Applying this technology in a small use case before slowly expanding it to others will produce a better return on investment.
While challenges remain, big data is already making waves in the pharmaceutical industry. This technology has the power to change the way researchers develop new medicines.
These improvements could lead to cheaper, more accessible drugs coming out in much shorter time frames. In turn, health outcomes would improve for a greater variety of patients. It all starts with recognizing the potential of big data.